格列本脲与皮下胰岛素对妊娠期糖尿病围产期并发症的关联
该研究基于2007至2017年Kaiser Permanente Northern California的11 321例需药物治疗的妊娠期糖尿病患者,采用机器学习与时间依赖暴露的因果推断方法(IPW联合Super Learning),比较启动格列本脲与胰岛素者的围产期结局。持续暴露于格列本脲者新生儿呼吸窘迫风险每100例出生低2.03(95%CI 0.13-3.92),NICU入住风险每100例出生低3.32(95%CI 0.20-6.45)。新生儿低血糖、黄疸、肩难产、大于胎龄儿风险差异均未达统计学显著。作者结论认为,未提供格列本脲与胰岛素在所查结局上存在差异的证据。
要点
- 在11 321例需药物治疗的妊娠期糖尿病患者中,持续暴露于格列本脲 vs 胰岛素:新生儿呼吸窘迫风险每100例出生低2.03(95%CI 0.13-3.92)。
- 持续暴露于格列本脲 vs 胰岛素:NICU入住风险每100例出生低3.32(95%CI 0.20-6.45)。
- 启动格列本脲 vs 胰岛素:新生儿低血糖风险每100例出生0.85(95%CI -1.17至2.86)、黄疸0.02(95%CI -1.46至1.51),差异未达统计学显著。
- 启动格列本脲 vs 胰岛素:肩难产风险每100例出生-1.05(95%CI -2.71至0.62)、大于胎龄儿-2.75(95%CI -6.31至0.80),差异未达统计学显著。
- 作者结论认为,未提供格列本脲与胰岛素在所查结局上存在差异的证据。
适用人群与场景
- 2007至2017年Kaiser Permanente Northern California中需药物治疗的妊娠期糖尿病患者,平均(SD)年龄32.9(4.9)岁。
研究设计与关键结果
- 研究类型:基于人群的队列研究,纳入2007至2017年Kaiser Permanente Northern California需药物治疗的妊娠期糖尿病患者11 321例。
- 方法:采用机器学习与严格因果推断方法(含时间依赖暴露),以逆概率加权(IPW)结合Super Learning估计倾向评分,分别比较启动格列本脲与胰岛素者的围产期结局,并进行符合方案(主要)与意向治疗(次要)分析以评估持续暴露于同一治疗。
- 主要结局(持续暴露,格列本脲 vs 胰岛素,每100例出生风险差):新生儿呼吸窘迫2.03(95%CI 0.13-3.92)更低;NICU入住3.32(95%CI 0.20-6.45)更低。
- 启动格列本脲 vs 胰岛素(每100例出生风险差):新生儿低血糖0.85(95%CI -1.17至2.86)、黄疸0.02(95%CI -1.46至1.51)、肩难产-1.05(95%CI -2.71至0.62)、大于胎龄儿-2.75(95%CI -6.31至0.80),差异均未达统计学显著。
- 数据分析时间为2018年3月至2017年7月(原文如此)。
证据类型、等级与局限
- 证据类型:基于人群的队列研究,采用因果推断方法(IPW联合Super Learning)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于需药物治疗的妊娠期糖尿病患者,作者结论认为未提供格列本脲与胰岛素在所查围产期结局上存在差异的证据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Nearly 30% of individuals with gestational diabetes (GDM) do not achieve glycemic control with lifestyle modification alone and require medication treatment. Oral agents, such as glyburide, have several advantages over insulin for the treatment of GDM, including greater patient acceptance; however, the effectiveness of glyburide for the treatment of GDM remains controversial.
OBJECTIVE: To compare the perinatal and neonatal outcomes associated with glyburide vs insulin using causal inference methods in a clinical setting with information on glycemic control.
DESIGN, SETTING, AND PARTICIPANTS: The population-based cohort study included patients with GDM who required medication treatment from 2007 to 2017 in Kaiser Permanente Northern California. Machine learning and rigorous casual inference methods with time-varying exposures were used to evaluate associations of exposure to glyburide vs insulin with perinatal outcomes. Data analysis was conducted from March 2018 to July 2017.
EXPOSURES: Time-varying exposure to glyburide vs insulin during pregnancy.
MAIN OUTCOMES AND MEASURES: Outcomes evaluated separately included neonatal hypoglycemia, jaundice, shoulder dystocia, respiratory distress syndrome (RDS), neonatal intensive care unit (NICU) admission, size-for-gestational age, and cesarean delivery. Inverse probability weighting (IPW) estimation was used to separately compare perinatal outcomes between those initiating glyburide and insulin. This approach was combined with Super Learning for propensity score estimation to account for both baseline and time-dependent confounding in both per-protocol (primary) and intention-to-treat (secondary) analyses to evaluate sustained exposure to the same therapy.
RESULTS: From 2007 to 2017, 11 321 patients with GDM (mean [SD] age, 32.9 [4.9] years) initiated glyburide or insulin during pregnancy. In multivariate models, the risk of neonatal respiratory distress was 2.03 (95% CI, 0.13-3.92) per 100 births lower and the risk of NICU admission was 3.32 (95% CI, 0.20-6.45) per 100 births lower after continuous exposure to glyburide compared with insulin. There were no statistically significant differences in glyburide vs insulin initiation in risk for neonatal hypoglycemia (0.85 [95% CI, -1.17 to 2.86] per 100 births), jaundice (0.02 [95% CI, -1.46 to 1.51] per 100 births), shoulder dystocia (-1.05 [95% CI, -2.71 to 0.62] per 100 births), or large-for-gestational age categories (-2.75 [95% CI, -6.31 to 0.80] per 100 births).
CONCLUSIONS AND RELEVANCE: Using data from a clinical setting and contemporary causal inference methods, our findings do not provide evidence of a difference in the outcomes examined between patients with GDM initiating glyburide compared with those initiating insulin.
参考来源
- Hedderson MM, Badon SE, Pimentel N, et al. Association of Glyburide and Subcutaneous Insulin With Perinatal Complications Among Women With Gestational Diabetes. JAMA Netw Open. 2022. PMID: 35357451. doi:10.1001/jamanetworkopen.2022.5026
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。